| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive Chairman/ Interim CEO | Director | Executive Chair. and Interim CEO
2 companies
Michael Martin Breen last filed a Form 4 in September 2025, as Director at PROP. The filings on record cover 2 companies. Michael Martin Breen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 856,218 shares of GTBP. Net of sales, the GTBP filings show accumulation of 50,000 shares.
Michael Martin Breen has 7 Form 4 filings on record from February 2021 to September 2025, across 2 companies: CEO and Director at GT Biopharma (GTBP), 2021–2025; Director at Prairie Operating (PROP), 2023.
The 17 reported transactions were 9 option or other derivative awards, 4 stock awards, 2 open-market purchases and 2 conversions.
Counted by filing, the open-market trades come to 2 purchases worth about $125K and no sales.
The largest open-market purchase was 916,112 shares of PROP at an average $0.11 on May 3, 2023, about $100K.
Shares as reported in the last Form 4 for each company; the most recent is from September 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.